Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 330-340

  Granata, A ^a   Nicoletti, R ^a   Tinaglia, V ^a   De Cecco, L ^a   Pisanu, M E ^b   Ricci, A ^b   Podo, F ^b   Canevari, S ^a   Iorio, E ^b   Bagnoli, M ^a   Mezzanzanica, D ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

cancer metabolism; choline kinase alpha; drug sensitivity; ovarian cancer; phosphocholine

Indexed keywords

CHOLINE KINASE; CHOLINE KINASE ALPHA; RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL AGGRESSIVENESS; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; IN VITRO STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; RNA INTERFERENCE;

CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLINE; CHOLINE KINASE; DOWN-REGULATION; DOXORUBICIN; FEMALE; HUMANS; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLCHOLINE; PLATINUM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84892904242     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.729     Document Type: Article

References (47)

1. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
2. Aoki J, Inoue A, Okudaira S (2008) Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781: 513-518.
3. Aoyama C, Liao H, Ishidate K (2004) Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281.
4. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi F, Mezzanzanica D, Canevari S (2011) Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2: 1265-1278.
5. Banez-Coronel M, de Molina AR, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA, Garcia-Oroz L, Lacal JC (2008) Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 8: 709-719.
6. Chon HS, Lancaster JM (2011) Microarray-based gene expression studies in ovarian cancer. Cancer Control 18: 8-15.
7. Chua BT, Gallego-Ortega D, Ramirez dM, Ullrich A, Lacal JC, Downward J (2009) Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Mol Cancer 8: 131.
8. Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, Trent JO, Chesney J (2011) A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene 30: 3370-3380.
9. de la Cueva A, Ramirez de Molina A, Varez-Ayerza N, Ramos MA, Cebrian A, Del Pulgar TG, Lacal JC (2013) Combined 5-FU and ChoKalpha inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One 8: e64961.
10. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279: 9653-9661.
11. Gallego-Ortega D, Gomez del PT, Valdes-Mora F, Cebrian A, Lacal JC (2011) Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul 51: 183-194.
12. Glunde K, Bhujwalla ZM, Ronen SM (2011a) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848.
13. Glunde K, Jiang L, Moestue SA, Gribbestad IS (2011b) MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed 24: 673-690.
14. Glunde K, Raman V, Mori N, Bhujwalla ZM (2005) RNA interferencemediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043.
15. Gruber J, See Too WC, Wong MT, Lavie A, McSorley T, Konrad M (2012) Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy. FEBS J 279: 1915-1928.
16. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
17. Hernandez-Alcoceba R, Fernandez F, Lacal JC (1999) In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 59: 3112-3118.
18. Iorio E, Di VM, Spadaro F, Ramoni C, Lococo E, Carnevale R, Lenti L, Strom R, Podo F (2003) Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. Biochim Biophys Acta 1634: 1-14.
19. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F (2005) Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65: 9369-9376.
20. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F (2010) Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 70: 2126-2135.
21. Iorio E, Ricci A, Pisanu ME, Bagnoli M, Podo F, Canevari S (2013) Choline metabolic profiling by magnetic resonance spectroscopy. Methods Mol Biol 1049: 255-270.
22. Ishidate K (1997) Choline/ethanolamine kinase from mammalian tissues. Biochim Biophys Acta 1348: 70-78.
23. Konstantinopoulos PA, Spentzos D, Cannistra SA (2008) Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5: 577-587.
24. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, Bhujwalla ZM (2009) Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res 69: 3464-3471.
25. Kurman RJ, Shih I (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
26. Mizuno K (2013) Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation. Cell Signal 25: 457-469.
27. Mori N, Gadiya M, Wildes F, Krishnamachary B, Glunde K, Bhujwalla ZM (2013) Characterization of choline kinase in human endothelial cells. NMR Biomed 26: 1501-1507.
28. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM (2007) Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res 67: 11284-11290.
29. Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65: 10794-10800.
30. Podo F (1999) Tumour phospholipid metabolism. NMR Biomed 12: 413-439.
31. Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E (2011) MR evaluation of response to targeted treatment in cancer cells. NMR Biomed 24: 648-672.
32. Ramirez dM, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez dM V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, Garcia-Cabezas MA, Sanchez JJ, Nistal M, Rosell R, Gonzalez-Baron M, Lacal JC (2007) Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 8: 889-897.
33. Rivera A, Mavila A, Bayless KJ, Davis GE, Maxwell SA (2006) Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell Mol Life Sci 63: 1425-1439.
34. Roberts RZ, Morris AJ (2000) Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid phosphate mediators. Biochim Biophys Acta 1487: 33-49.
35. Rodriguez-Gonzalez A, Ramirez de MA, Banez-Coronel M, Megias D, Lacal JC (2005) Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 26: 999-1008.
36. Rodriguez-Gonzalez A, Ramirez de MA, Fernandez F, Ramos MA, del Carmen NM, Campos J, Lacal JC (2003) Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 22: 8803-8812.
37. Sandercock J, Parmar MK, Torri V, Qian W (2002) First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 87: 815-824.
38. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
39. So J, Navari J, Wang FQ, Fishman DA (2004) Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 95: 314-322.
40. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F (2008) Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res 68: 6541-6549.
41. Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, Ellis JK, Lau CH, Keun HC, Schmitz G, Schiller J, Eibisch M, Hedberg C, Waldmann H, Lausch E, Tanner B, Sehouli J, Sagemueller J, Staude H, Steiner E, Hengstler JG (2012) Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci USA 109: 8155-8160.
42. Vance JE, Vance DE (2004) Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol 82: 113-128.
43. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
44. Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: 719-725.
45. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308.
46. Wu G, Aoyama C, Young SG, Vance DE (2008) Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem 283: 1456-1462.
47. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J (2010) Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 29: 139-149.